

Colin J Mckay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10626539/publications.pdf>

Version: 2024-02-01

37
papers

4,316
citations

257450

24
h-index

434195

31
g-index

38
all docs

38
docs citations

38
times ranked

6007
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1073.	7.4	1,206
2	IAP Guidelines for the surgical management of acute pancreatitis. <i>Pancreatology</i> , 2002, 2, 565-573.	1.1	430
3	Percutaneous Necrosectomy and Sinus Tract Endoscopy in the Management of Infected Pancreatic Necrosis: An Initial Experience. <i>Annals of Surgery</i> , 2000, 232, 175-180.	4.2	363
4	Rab25 and CLIC3 Collaborate to Promote Integrin Recycling from Late Endosomes/Lysosomes and Drive Cancer Progression. <i>Developmental Cell</i> , 2012, 22, 131-145.	7.0	275
5	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	223
6	Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2010, 251, 1003-1010.	4.2	178
7	Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. <i>Pancreatology</i> , 2006, 6, 450-453.	1.1	147
8	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	1.6	142
9	LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest. <i>Gastroenterology</i> , 2010, 139, 586-597.e6.	1.3	130
10	Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2011, 17, 3316-3331.	7.0	114
11	Targeting mTOR dependency in pancreatic cancer. <i>Gut</i> , 2014, 63, 1481-1489.	12.1	107
12	A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 2318-2328.	1.5	104
13	IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. <i>Oncotarget</i> , 2014, 5, 11064-11080.	1.8	103
14	Chronic inflammation and pancreatic cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 65-73.	2.4	97
15	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
16	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 887-898.	1.7	80
17	The Prognostic Influence of Resection Margin Clearance Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 511-521.	1.7	80
18	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	6.4	78

#	ARTICLE	IF	CITATIONS
19	Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. <i>Hpb</i> , 2014, 16, 610-619.	0.3	67
20	The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3581-3590.	1.5	61
21	SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0131344.	2.5	51
22	Precision Oncology in Surgery. <i>Annals of Surgery</i> , 2020, 272, 366-376.	4.2	48
23	Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. <i>BMC Clinical Pathology</i> , 2014, 14, 35.	1.8	32
24	â€Stepâ€portâ€™ laparoscopic cystgastrostomy for the management of organized solid predominant postâ€acute fluid collections after severe acute pancreatitis. <i>Hpb</i> , 2014, 16, 170-176.	0.3	30
25	Infected pancreatic necrosis: minimizing the cut. <i>ANZ Journal of Surgery</i> , 2010, 80, 58-70.	0.7	27
26	Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 512-524.	1.7	25
27	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.	1.4	12
28	IAP Guidelines for the Surgical Management of Acute Pancreatitis. <i>Pancreatology</i> , 2003, 3, 565-573.	1.1	11
29	Investigation and management of pancreatic tumours. <i>Frontline Gastroenterology</i> , 2014, 5, 144-152.	1.8	2
30	Routine Drainage After Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2015, 262, e107.	4.2	1
31	RE: <i>nab</i> -Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv204.	6.3	1
32	Management of acute pancreatitis and complications. , 2017, , 897-910.e2.		1
33	The Challenges of Improving Survival Following Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2011, 254, 386.	4.2	0
34	Reply to G.F. Arroyo. <i>Journal of Clinical Oncology</i> , 2013, 31, 3843-3844.	1.6	0
35	Management of Necrotizing Pancreatitis. , 2009, , 1151-1160.		0
36	Management of Necrotizing Pancreatitis. , 2010, , 3-15.		0

#	ARTICLE	IF	CITATIONS
37	Strategies for Surgical Treatment of Chronic Pancreatitis. , 0, , 537-560.		0